Kaihang Yu1, Weiliang Zeng2, Ye Xu1, Wenli Liao1, Wenya Xu1, Tieli Zhou1, Jianming Cao3, Lijiang Chen4. 1. Department of Clinical Laboratory, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. 2. School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, 325000, China. 3. School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, 325000, China. wzcjming@163.com. 4. Department of Clinical Laboratory, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China. wyychenlijiang@163.com.
Abstract
BACKGROUND: Bloodstream infection (BSI) caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) has been increasingly observed among hospitalized patients. The following study analyzed the epidemiology and microbiological characteristics of MDR-AB, as well as the clinical features, antimicrobial treatments, and outcomes in patients over a six years period in China. METHODS: This retrospective study was conducted in a large tertiary hospital in China between January 2013 and December 2018. The clinical and microbiological data of all consecutive hospitalized patients with MDR-AB induced bloodstream infection were included and analyzed. RESULTS: A total of 108 BSI episodes were analyzed. All MDR isolates belonged to ST2, a sequence type that has spread all over the world. Overall, ST2 strains showed strong biofilm formation ability, high serum resistance, and high pathogenicity. As for the clinical characteristics of the patient, 30-day mortality was 69.4% (75/108). The three main risk factors included mechanical ventilation, intensive care unit (ICU) stay, and thrombocytopenia; three protective factors included a change of antimicrobial regimen within 48 h after positive blood culture, use of the antibacterial agent combination, and more inpatient days. The most effective antibacterial regimen was the combination of cefoperazone/sulbactam and tigecycline. CONCLUSIONS: BSI caused by ST2 A.baumannii represents a difficult challenge for physicians, considering the high mortality associated with this infection. The combination of cefoperazone/sulbactam and tigecycline may be an effective treatment option.
BACKGROUND:Bloodstream infection (BSI) caused by multidrug-resistant Acinetobacter baumannii (MDR-AB) has been increasingly observed among hospitalized patients. The following study analyzed the epidemiology and microbiological characteristics of MDR-AB, as well as the clinical features, antimicrobial treatments, and outcomes in patients over a six years period in China. METHODS: This retrospective study was conducted in a large tertiary hospital in China between January 2013 and December 2018. The clinical and microbiological data of all consecutive hospitalized patients with MDR-AB induced bloodstream infection were included and analyzed. RESULTS: A total of 108 BSI episodes were analyzed. All MDR isolates belonged to ST2, a sequence type that has spread all over the world. Overall, ST2 strains showed strong biofilm formation ability, high serum resistance, and high pathogenicity. As for the clinical characteristics of the patient, 30-day mortality was 69.4% (75/108). The three main risk factors included mechanical ventilation, intensive care unit (ICU) stay, and thrombocytopenia; three protective factors included a change of antimicrobial regimen within 48 h after positive blood culture, use of the antibacterial agent combination, and more inpatient days. The most effective antibacterial regimen was the combination of cefoperazone/sulbactam and tigecycline. CONCLUSIONS: BSI caused by ST2A.baumannii represents a difficult challenge for physicians, considering the high mortality associated with this infection. The combination of cefoperazone/sulbactam and tigecycline may be an effective treatment option.
Authors: Thomas A Russo; Nicole R Luke; Janet M Beanan; Ruth Olson; Shauna L Sauberan; Ulrike MacDonald; L Wayne Schultz; Timothy C Umland; Anthony A Campagnari Journal: Infect Immun Date: 2010-07-19 Impact factor: 3.441
Authors: José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti Journal: Intensive Care Med Date: 2015-10-05 Impact factor: 17.440
Authors: Nicole R Luke; Shauna L Sauberan; Thomas A Russo; Janet M Beanan; Ruth Olson; Thomas W Loehfelm; Andrew D Cox; Frank St Michael; Evgeny V Vinogradov; Anthony A Campagnari Journal: Infect Immun Date: 2010-03-01 Impact factor: 3.441
Authors: Anna C Jacobs; Indriati Hood; Kelli L Boyd; Patrick D Olson; John M Morrison; Steven Carson; Khalid Sayood; Peter C Iwen; Eric P Skaar; Paul M Dunman Journal: Infect Immun Date: 2010-03-01 Impact factor: 3.441
Authors: Evelina Tacconelli; Elena Carrara; Alessia Savoldi; Stephan Harbarth; Marc Mendelson; Dominique L Monnet; Céline Pulcini; Gunnar Kahlmeter; Jan Kluytmans; Yehuda Carmeli; Marc Ouellette; Kevin Outterson; Jean Patel; Marco Cavaleri; Edward M Cox; Chris R Houchens; M Lindsay Grayson; Paul Hansen; Nalini Singh; Ursula Theuretzbacher; Nicola Magrini Journal: Lancet Infect Dis Date: 2017-12-21 Impact factor: 71.421
Authors: Michal Magda; Serena Bettoni; Maisem Laabei; Derek Fairley; Thomas A Russo; Kristian Riesbeck; Anna M Blom Journal: Front Immunol Date: 2022-01-31 Impact factor: 8.786